- Home
- OCX vs FGEN Comparison
OCX vs FGEN Comparison
Compare OCX & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCX
- FGEN
- Stock Information
- Founded
- OCX 2009
- FGEN 1993
- Country
- OCX United States
- FGEN United States
- Employees
- OCX N/A
- FGEN N/A
- Industry
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- OCX Health Care
- FGEN Health Care
- Exchange
- OCX Nasdaq
- FGEN Nasdaq
- Market Cap
- OCX 38.7M
- FGEN 34.0M
- IPO Year
- OCX N/A
- FGEN 2014
- Fundamental
- Price
- OCX $2.61
- FGEN $0.33
- Analyst Decision
- OCX Buy
- FGEN
- Analyst Count
- OCX 3
- FGEN 0
- Target Price
- OCX $4.42
- FGEN N/A
- AVG Volume (30 Days)
- OCX 64.0K
- FGEN 1.6M
- Earning Date
- OCX 11-12-2024
- FGEN 11-12-2024
- Dividend Yield
- OCX N/A
- FGEN N/A
- EPS Growth
- OCX N/A
- FGEN N/A
- EPS
- OCX N/A
- FGEN N/A
- Revenue
- OCX $709,000.00
- FGEN $180,015,000.00
- Revenue This Year
- OCX N/A
- FGEN $20.42
- Revenue Next Year
- OCX $167.93
- FGEN N/A
- P/E Ratio
- OCX N/A
- FGEN N/A
- Revenue Growth
- OCX N/A
- FGEN 16.15
- 52 Week Low
- OCX $2.29
- FGEN $0.18
- 52 Week High
- OCX $4.34
- FGEN $2.93
- Technical
- Relative Strength Index (RSI)
- OCX 30.23
- FGEN 48.26
- Support Level
- OCX $2.73
- FGEN $0.18
- Resistance Level
- OCX $3.04
- FGEN $0.43
- Average True Range (ATR)
- OCX 0.14
- FGEN 0.05
- MACD
- OCX -0.03
- FGEN 0.01
- Stochastic Oscillator
- OCX 0.00
- FGEN 63.14
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.